Denmark· DK-28107045223
Balversa
A erdafitinib product containing erdafitinib, registered in Denmark by Janssen-Cilag International NV. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Erdafitinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EN01 (erdafitinib), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Erdafitinib · ATC L01EN01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of erdafitinib costs, country by country.
Normalised to the WHO defined daily dose (9 mg), the median price runs from $0.55 in France to $621.10 in Switzerland — a ×1128 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Erdafitinib · price per daily dose (9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$621.10
- FR France$0.55
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Erdafitinib
- Manufacturer
- Janssen-Cilag International NV
- Country
- Denmark (DK)
- ATC code
- L01EN01
- ATC class
- Erdafitinib
- Defined daily dose
- 9 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107045223
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
154 interactions on record for erdafitinib.
Graded by severity as the source publishes them — 56 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Erdafitinib · interactions on record
154 records
- 56 severe
- 98 moderate
Most severe, free to view
- Magnesium carbonateA02AA01severe
- Magnesium oxideA02AA02severe
- Magnesium hydroxideA02AA04severe
- Kombinationen von AluminiumsalzenA02AB10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EN01
Erdafitinib, as other registers publish it.
- IcelandBalversaJanssen-Cilag International NV*
- IcelandBalversaJanssen-Cilag International NV*
- FinlandBalversaJanssen Cilag International
- PolandBalversaJanssen-Cilag International N.V.
- DenmarkBalversaJanssen-Cilag International NV
- IcelandBalversaJanssen-Cilag International NV*
- FinlandBalversaJanssen Cilag International
- NorwayBalversaJanssen-Cilag International N.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ff0b39d3-d4c0-4f3a-a4da-5d21d50dff44 GET /v1/drugs/ff0b39d3-d4c0-4f3a-a4da-5d21d50dff44?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "3 mg",
"auth_role": "MOD",
"dk_drugid": "28107045223",
"substance": "Erdafitinib",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "45526"
}See everything about erdafitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.